<?xml version='1.0' encoding='utf-8'?>
<document id="10681383"><sentence text="Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent." /><sentence text="Testosterone, terfenadine, midazolam, and nifedipine, four commonly used substrates for human cytochrome P-450 3A4 (CYP3A4), were studied in pairs in human liver microsomes and in microsomes from cells containing recombinant human CYP3A4 and P-450 reductase, to investigate in vitro substrate-substrate interaction with CYP3A4"><entity charOffset="0-12" id="DDI-PubMed.10681383.s2.e0" text="Testosterone" /><entity charOffset="14-25" id="DDI-PubMed.10681383.s2.e1" text="terfenadine" /><entity charOffset="27-36" id="DDI-PubMed.10681383.s2.e2" text="midazolam" /><entity charOffset="42-52" id="DDI-PubMed.10681383.s2.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e0" e2="DDI-PubMed.10681383.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e0" e2="DDI-PubMed.10681383.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e0" e2="DDI-PubMed.10681383.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e0" e2="DDI-PubMed.10681383.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e1" e2="DDI-PubMed.10681383.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e1" e2="DDI-PubMed.10681383.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e1" e2="DDI-PubMed.10681383.s2.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e2" e2="DDI-PubMed.10681383.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s2.e2" e2="DDI-PubMed.10681383.s2.e3" /></sentence><sentence text=" The interaction patterns between compounds with CYP3A4 were found to be substrate-dependent" /><sentence text=" Mutual inhibition, partial inhibition, and activation were observed in the testosterone-terfenadine, testosterone-midazolam, or terfenadine-midazolam interactions"><entity charOffset="76-88" id="DDI-PubMed.10681383.s4.e0" text="testosterone" /><entity charOffset="89-100" id="DDI-PubMed.10681383.s4.e1" text="terfenadine" /><entity charOffset="102-114" id="DDI-PubMed.10681383.s4.e2" text="testosterone" /><entity charOffset="115-124" id="DDI-PubMed.10681383.s4.e3" text="midazolam" /><entity charOffset="129-140" id="DDI-PubMed.10681383.s4.e4" text="terfenadine" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e0" e2="DDI-PubMed.10681383.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e0" e2="DDI-PubMed.10681383.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e0" e2="DDI-PubMed.10681383.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e0" e2="DDI-PubMed.10681383.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e0" e2="DDI-PubMed.10681383.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e1" e2="DDI-PubMed.10681383.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e1" e2="DDI-PubMed.10681383.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e1" e2="DDI-PubMed.10681383.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e1" e2="DDI-PubMed.10681383.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e2" e2="DDI-PubMed.10681383.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e2" e2="DDI-PubMed.10681383.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e2" e2="DDI-PubMed.10681383.s4.e4" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e3" e2="DDI-PubMed.10681383.s4.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s4.e3" e2="DDI-PubMed.10681383.s4.e4" /></sentence><sentence text=" However, the most unusual result was the interaction between testosterone and nifedipine"><entity charOffset="62-74" id="DDI-PubMed.10681383.s5.e0" text="testosterone" /><entity charOffset="79-89" id="DDI-PubMed.10681383.s5.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.10681383.s5.e0" e2="DDI-PubMed.10681383.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10681383.s5.e0" e2="DDI-PubMed.10681383.s5.e1" /></sentence><sentence text=" Although nifedipine inhibited testosterone 6beta-hydroxylation in a concentration-dependent manner, testosterone did not inhibit nifedipine oxidation"><entity charOffset="10-20" id="DDI-PubMed.10681383.s6.e0" text="nifedipine" /><entity charOffset="31-43" id="DDI-PubMed.10681383.s6.e1" text="testosterone" /><entity charOffset="101-113" id="DDI-PubMed.10681383.s6.e2" text="testosterone" /><entity charOffset="130-140" id="DDI-PubMed.10681383.s6.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e0" e2="DDI-PubMed.10681383.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e0" e2="DDI-PubMed.10681383.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e0" e2="DDI-PubMed.10681383.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e0" e2="DDI-PubMed.10681383.s6.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e1" e2="DDI-PubMed.10681383.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e1" e2="DDI-PubMed.10681383.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e1" e2="DDI-PubMed.10681383.s6.e3" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e2" e2="DDI-PubMed.10681383.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10681383.s6.e2" e2="DDI-PubMed.10681383.s6.e3" /></sentence><sentence text=" Furthermore, the effect of testosterone and 7,8-benzoflavone on midazolam 1'-hydroxylation and 4-hydroxylation demonstrated different regiospecificities"><entity charOffset="28-40" id="DDI-PubMed.10681383.s7.e0" text="testosterone" /><entity charOffset="45-61" id="DDI-PubMed.10681383.s7.e1" text="7,8-benzoflavone" /><pair ddi="false" e1="DDI-PubMed.10681383.s7.e0" e2="DDI-PubMed.10681383.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10681383.s7.e0" e2="DDI-PubMed.10681383.s7.e1" /></sentence><sentence text=" These results may be explained by a model in which multiple substrates or ligands can bind concurrently to the active site of a single CYP3A4 molecule" /><sentence text=" However, the contribution of separate allosteric sites and conformational heterogeneity to the atypical kinetics of CYP3A4 can not be ruled out in this model" /><sentence text="" /></document>